TrialNet participant Hollie Shereyk poses with her 3 sisters standing in front of a doorway
Participant Spotlight
Read more
Growing up with TrialNet — Screened as children and now in their 20s, two Abatacept Prevention Study participants share their stories
As we near the release of findings from the Abatacept Prevention Study, two participants share how their experiences in TrialNet research helped shape their futures.
An illustration of TrialNet hero Orlando Brown, Jr. wearing a football uniform and holding up a round shield to deflect a lightning bolt
Participant Spotlight
Read more
Meet TrialNet hero: Orlando Brown, Jr.
Meet Orlando Brown, Jr.: You may recognize the Kansas City Chiefs offensive tackle, also known as “Zeus”. It’s evident why, especially on the gridiron. More than 350 pounds of superhuman muscle and momentum sprinting downfield, Orlando inherited the name and strength of his father, also an NFL hero.
TrialNet Research Leads to FDA Approval of First Drug to Delay Type 1 Diabetes
Media Release
Read more
TrialNet Research Leads to FDA Approval of First Drug to Delay Type 1 Diabetes
Landmark findings from TrialNet research were instrumental in the Food and Drug Administration’s (FDA) November 17, 2022 approval of the first drug to delay type 1 diabetes (T1D) in people at risk.
TrialNet conducted the clinical study that discovered the immunotherapy drug teplizumab could delay T1D for 2+ years.
